Trial Profile
A study investigating rimonabant versus placebo in conjunction with a strict low-fat weight reduction diet in overweight and obese subjects: effects on glucose and lipid metabolism and cardiovascular risk.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Sep 2021
Price :
$35
*
At a glance
- Drugs Rimonabant (Primary)
- Indications Obesity
- Focus Therapeutic Use
- 01 Aug 2010 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials.
- 29 Sep 2008 New trial record.